SpecificationsOrganism/cell line/tissueHomo sapiensSexFemaleSequencer or array typeIllumina Hiseq 2000 genome analyzerData formatRaw: SRA study; processed: BEDExperimental factorsPoor vs. good outcome tumorsExperimental featuresGenome-wide binding of Estrogen Receptor α (ERα), as well as histone marks H3K4me3 and H3K27me3, were assessed in tumors from breast cancer patients with good or poor survival outcome after aromatase inhibitors therapy.ConsentAll patients gave their written informed consent before study entry.Sample source locationSamples were from breast cancer patients, treated at the Erasmus University Medical Center (EMC; Rotterdam, the Netherlands), the Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (Amsterdam, the Netherlands), and the Translational Cancer Research Unit (Saint Augustinus Hospital, Antwerpen, Belgium).

Direct link to deposited data {#s0010}
=============================

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40867>.

Experimental design, materials and methods {#s0015}
==========================================

Study population and clinical data {#s0020}
----------------------------------

The cohort of 84 metastatic ERα-positive breast cancer patients, who received AI therapy, was selected for evaluation. Tumor material analyzed by genomic profiling was extracted from primary surgery specimens. The patient selection criteria, definitions of follow-up, tumor staging, and response to therapy were previously described by Ramirez-Ardila et al. [@bb0025]. Briefly, fresh frozen ERα-positive breast tumor tissue specimens were collected from female patients with primary operable breast cancer and whose metastatic disease was treated with first-line aromatase inhibitors (anastrozole, letrozole, exemestane). Time to progression (TTP) was taken as the end point. Thirteen specimens were selected for chromatin immunoprecipitation (ChIP) and massive parallel sequencing (ChIP-seq) analyses, all on samples with more than 50% ER-positive tumor cells. Poor outcome patients were defined as patients with a TTP \< 12 months, whereas good outcome patients were defined as patients with a TTP \> 24 months. Clinical characteristics of the selected groups of patients are provided in [Table 1](#t0005){ref-type="table"} and clinical characteristics per sample are provided in the [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}.

The anonymized clinical data were deposited in the Gene Expression Omnibus database (GEO; [@bb0030]) under accession number [GSE40867](ncbi-geo:GSE40867){#ir0405}.

Chromatin immunoprecipitations and sequencing {#s0025}
---------------------------------------------

Chromatin immunoprecipitation (ChIP) was performed as described before [@bb0020]. To obtain input material, tumor samples were cryosectioned (30 × 30 mm sections) prior to further processing for ChIP-seq as described before [@bb0035]. For each ChIP, 10 mg of antibody and 100 mL of Protein A magnetic beads (Invitrogen) were used. Antibodies against ERα (SC-543; Santa Cruz), H3K4me3 (ab8580; Abcam), and H3K27me3 (07--449; Millipore) were used.

ChIP DNA was amplified as described [@bb0020], [@bb0035]. Sequences were generated by the Illumina Hiseq 2000 genome analyzer (using 50 bp reads), and aligned to the Human Reference Genome (assembly hg19, February 2009). Non-ChIP input DNA from a randomly selected tumor was sequenced as an input control. Enriched regions of the genome were identified by comparing the ChIP samples to input using the MACS peak caller [@bb0040] version 1.3.7.1 with default parameters, except for the p-value cutoff that was set at 10^− 7^. Details on the number of reads obtained, the percentage of reads aligned, and the number of peaks called can be found in [Table 2](#t0010){ref-type="table"}. ChIP-seq data and sample annotations were deposited in GEO under accession number [GSE40867](ncbi-geo:GSE40867){#ir0410}.

Quality control {#s0030}
---------------

Prior to analysis, visual inspection of the regions known to typically bind ERα or contain histone modifications was performed using the Integrative Genome Viewer IGV 2.1 ([www.broadinstitute.org/igv/](http://www.broadinstitute.org/igv/){#ir0415}). Examples of such regions are provided in [Fig. 1](#f0005){ref-type="fig"}A. As expected, ERα peaks were found at the enhancers of known estrogen-responsive genes (e.g. XBP1 ([Fig. 1](#f0005){ref-type="fig"}A), RARA, GREB1), H3K4me3 signal was observed at promoters of estrogen-responsive genes and H3K27me3 marked genes not expressed in breast tissue, such as NEUROD1. ([Fig. 1](#f0005){ref-type="fig"}A). The peaks of H3K4me3 histone modification are often wider than the peaks of ERα binding [@bb0045], while the transcription repressive histone mark H3K27me3 can cover large areas, including full gene bodies [@bb0050], which also results in the identification of broad peaks for this histone mark. Peak widths for all three datasets are illustrated by the density distributions as depicted in [Fig. 1](#f0005){ref-type="fig"}B.

There is no current consensus on the quality control metrics for ChIP- and enrichment-based technologies, such as ChIP-seq, GRO-seq and others. Commonly, the number of reads and peaks detected is reported. The total number of reads, number of aligned reads and number of peaks for each ChIP-seq sample are shown in [Table 2](#t0010){ref-type="table"}. A few quality control procedures have been suggested in the literature [@bb0055], [@bb0060], however their use is not established practice and some of them may not be applicable to a large variety of ChIP-seq data.

Here we employed quality control measures suggested by the ENCODE consortium for assessing the quality of the data [@bb0055]. It is, however, important to mention that ENCODE guidelines are used in the analysis of the data from cell line experiments. Data from tumor samples, used in the current study, are more difficult to process due to intrinsic intra-tumor heterogeneity and biological variation. Therefore, we cannot expect our tumor sample-based ChIP-seq data to fully meet the criteria used for the cell line data. The minimal fraction of reads in peaks as prescribed by ENCODE (1%), which is an indicator of ChIP efficiency, was met in almost 80% of the samples ([Table 2](#t0010){ref-type="table"}). Cross-correlations of positive and negative strands were calculated using publicly available scripts (<http://code.google.com/p/phantompeakqualtools)> [@bb0065], [@bb0070]. An example of a cross-correlation plot can be seen in [Fig. 1](#f0005){ref-type="fig"}C. Dominant fragment and read lengths were calculated from the cross-correlations, and the related measures, namely Normalized Strand Coefficient (NSC) and Relative Strand Correlation (RSC), were assessed. As can be seen from [Table 2](#t0010){ref-type="table"}, not all the samples meet the ENCODE criteria of NSC \> 1.05 and RSC \> 0.8. The best results for these parameters are achieved in the H3K4me3 data with over 90% meeting the NSC criterion and over 60% meeting the RSC criterion. Overall, the quality metrics for ERα ChIP-seq have lower values than those for the histone marks. However, it is not surprising for a number of reasons. First, immunoprecipitation of chromatin with histone marks is more efficient as histones are the intrinsic part of the chromatin, whereas ERα is a transcription factor not integrated in the structure of chromatin. Second, being a hormone-dependent transcription factor, ERα chromatin interactions are dependent on the physiological levels of E2, which may be at non-saturated levels within the tumor and could vary from patient to patient. Third, as shown before, high quality ChIP-seq datasets with limited number of genuine binding sites may produce low NSC and RSC values [@bb0055].

We further validated that the peaks detected in ERα ChIP-seq data are genuine signal and correspond to the binding sites of ERα. Called peaks that were found in at least two tumor samples were considered for analysis, resulting in 11,262 peaks for ERα dataset. This high number of consensus peaks illustrates the quality of the data available for the analysis. We subsequently defined the locations of ERα motifs in these peaks by using the ScreenMotif tool from the Cistrome (cistrome.org). As seen from the [Fig. 1](#f0005){ref-type="fig"}D, the motifs are clearly concentrated around the center of identified peaks. This illustrates that despite the NSC and RSC metrics having marginal values, the ERα peaks detected present a genuine signal. R scripts for analysis are available upon request.

Discussion {#s0005}
==========

Here we describe a unique dataset, in which we profiled the chromatin binding landscapes of ERα, H3K4me3 and H3K27me3 in primary human ERα-positive luminal breast tumor specimens. Patients were treated in the metastatic setting with AIs, and survival data are available and provided in the public data repositories. With this, our datasets consist of two parts: clinical and ChIP-seq data. Clinical data includes outcome upon treatment with aromatase inhibitors and other important clinic-pathological characteristics. ChIP-seq data comprises genome-wide profiling of estrogen receptor (ERα) binding to chromatin, promoter-specific histone modification H3K4me3 and transcription repressive histone mark H3K27me3. This dataset has been recently used in a publication for finding epigenetic signatures related to the outcome upon aromatase inhibitors treatment for metastatic breast cancer [@bb0020].

The following are the supplementary data related to this article.Supplementary Table S1.Clinicopathological paramater of patient series.
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###### 

Patient and tumor characteristics for the selected groups.

  Patients (n = 13)                         
  ------------------------------------ ---- -----
                                       5    8
  Age at diagnosis (mean), years       64   60
  Age at start therapy (mean), years   68   63
  Treatment type                            
   Anastrozole                         2    5
   Exemestane                          0    1
   Exemestane                          0    1
   Letrozole                           3    1
  Grade                                     
   1                                   1    0
   2                                   3    3
   3                                   1    4
  ER status                                 
   Negative                            0    0
   Positive                            5    8
  PR status                                 
   Negative                            0    0
   Positive                            5    8
  HER2 status                               
   Negative                            3    5
   Positive                            1    1
  TTP (median), months                 38   6.5

###### 

Read count, number of peaks and quality parameters.

  GEO accession                                ChIP       Total reads   Mapped reads (%)    No of peaks   Fraction of reads in peaks, %   NSC    RSC
  -------------------------------------------- ---------- ------------- ------------------- ------------- ------------------------------- ------ ------
  [GSM1003708](ncbi-geo:GSM1003708){#ir0215}   ERα        23,760,885    21,964,709 (92.4)   524           0.15                            1.02   0.48
  [GSM1003709](ncbi-geo:GSM1003709){#ir0220}   H3K4me3    22,772,852    20,520,046 (90.1)   16,384        26.35                           1.64   1.72
  [GSM1003710](ncbi-geo:GSM1003710){#ir0225}   H3K27me3   26,990,559    26,122,735 (96.8)   14,890        3.56                            1.01   0.46
  [GSM1003711](ncbi-geo:GSM1003711){#ir0230}   ERα        23,802,294    22,002,226 (92.4)   2255          0.6                             1.02   0.47
  [GSM1003712](ncbi-geo:GSM1003712){#ir0235}   H3K4me3    22,591,289    20,813,064 (92.1)   16,857        31.03                           1.61   1.49
  [GSM1003713](ncbi-geo:GSM1003713){#ir0240}   H3K27me3   22,096,326    21,343,362 (96.6)   10,078        2.91                            1.01   0.32
  [GSM1003714](ncbi-geo:GSM1003714){#ir0245}   ERα        20,789,758    17,832,808 (85.8)   15,381        4.38                            1.09   0.89
  [GSM1003715](ncbi-geo:GSM1003715){#ir0250}   H3K4me3    23,075,271    20,411,990 (88.5)   25,111        11.97                           1.07   0.53
  [GSM1003716](ncbi-geo:GSM1003716){#ir0255}   H3K27me3   19,103,286    17,130,759 (89.7)   4008          1.48                            1.02   0.32
  [GSM1003717](ncbi-geo:GSM1003717){#ir0260}   ERα        22,555,195    21,115,239 (93.6)   2726          0.84                            1.04   0.76
  [GSM1003718](ncbi-geo:GSM1003718){#ir0265}   H3K4me3    19,872,399    18,226,845 (91.7)   16,320        9.05                            1.05   0.44
  [GSM1003719](ncbi-geo:GSM1003719){#ir0270}   H3K27me3   23,961,464    22,493,285 (93.9)   3085          0.64                            1.02   0.39
  [GSM1003720](ncbi-geo:GSM1003720){#ir0275}   ERα        16,604,876    15,605,068 (94.0)   13,575        3.61                            1.09   1.03
  [GSM1003721](ncbi-geo:GSM1003721){#ir0280}   H3K4me3    10,238,004    9,467,187 (92.5)    19,012        6.69                            1.09   0.33
  [GSM1003722](ncbi-geo:GSM1003722){#ir0285}   H3K27me3   22,530,535    21,625,249 (96.0)   33,661        9.13                            1.04   0.83
  [GSM1003723](ncbi-geo:GSM1003723){#ir0290}   ERα        19,902,396    18,778,288 (94.4)   6387          1.46                            1.04   0.7
  [GSM1003724](ncbi-geo:GSM1003724){#ir0295}   H3K4me3    20,235,985    18,151,245 (89.7)   18,351        41.23                           1.83   1.56
  [GSM1003725](ncbi-geo:GSM1003725){#ir0300}   H3K27me3   24,169,596    23,067,266 (95.4)   30,588        7.44                            1.02   0.42
  [GSM1003726](ncbi-geo:GSM1003726){#ir0305}   ERα        16,011,312    13,905,708 (86.8)   2287          0.58                            1.02   0.41
  [GSM1003727](ncbi-geo:GSM1003727){#ir0310}   H3K27me3   16,423,400    15,482,959 (94.2)   28,514        7.34                            1.03   0.57
  [GSM1003728](ncbi-geo:GSM1003728){#ir0315}   ERα        21,552,073    17,908,925 (83.1)   709           0.72                            1.02   0.31
  [GSM1003729](ncbi-geo:GSM1003729){#ir0320}   H3K4me3    27,693,755    25,171,058 (90.9)   27,023        15.47                           1.16   1.03
  [GSM1003730](ncbi-geo:GSM1003730){#ir0325}   H3K27me3   27,372,177    24,765,816 (90.5)   11,395        1.28                            1.02   0.67
  [GSM1003731](ncbi-geo:GSM1003731){#ir0330}   ERα        15,620,215    14,134,239 (90.5)   5170          2.48                            1.05   0.72
  [GSM1003732](ncbi-geo:GSM1003732){#ir0335}   H3K4me3    20,741,336    18,816,604 (90.7)   26,821        14.94                           1.1    0.57
  [GSM1003733](ncbi-geo:GSM1003733){#ir0340}   H3K27me3   21,310,477    20,553,892 (96.4)   27,122        3.28                            1.02   0.49
  [GSM1003734](ncbi-geo:GSM1003734){#ir0345}   ERα        18,169,785    16,090,891 (88.6)   19,716        5.43                            1.14   1.19
  [GSM1003735](ncbi-geo:GSM1003735){#ir0350}   H3K4me3    26,621,106    24,586,405 (92.4)   23,785        1.58                            1.11   0.87
  [GSM1003736](ncbi-geo:GSM1003736){#ir0355}   H3K27me3   26,069,531    25,135,569 (96.4)   59,910        22.03                           1.06   1.23
  [GSM1003737](ncbi-geo:GSM1003737){#ir0360}   ERα        20,867,111    18,925,868 (90.7)   1110          0.29                            1.01   0.37
  [GSM1003738](ncbi-geo:GSM1003738){#ir0365}   H3K4me3    20,012,887    17,988,530 (89.9)   16,427        22.24                           1.38   1.41
  [GSM1003739](ncbi-geo:GSM1003739){#ir0370}   H3K27me3   23,750,330    22,949,910 (96.6)   4256          0.79                            1.01   0.33
  [GSM1003740](ncbi-geo:GSM1003740){#ir0375}   ERα        13,499,179    12,530,097 (92.8)   924           1.76                            1.02   0.33
  [GSM1003741](ncbi-geo:GSM1003741){#ir0380}   H3K4me3    26,027,543    24,076,775 (92.5)   26,396        11.24                           1.13   0.96
  [GSM1003742](ncbi-geo:GSM1003742){#ir0385}   H3K27me3   31,996,441    30,602,420 (95.6)   7067          1.13                            1.03   0.86
  [GSM1003743](ncbi-geo:GSM1003743){#ir0390}   Input      27,097,497    25,588,905 (94.4)                                                        
